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Abstract
Background: In a previous report we have demonstrated that the chymotryptic-like serine
protease kallikrein 7 (KLK7/hK7) is overexpressed in pancreatic cancer. In normal skin, hK7 is
thought to participate in skin desquamation by contributing in the degradation of desmosomal
components, such as desmogleins. Thus, the ability of hK7 to degrade desmogleins was assessed
and the effect of hK7 expression on desmoglein 2 was examined in cultured pancreatic cancer cells.
Methods:  The expression of Dsg1, Dsg2, and Dsg3 in pancreatic tissues was examined by
immunohistochemistry and their expression in two pancreatic cancer cell lines, BxPC-3 and Panc-
1, was determined by western blot analysis. The ability of hK7 to degrade Dsg1 and Dsg2 was
investigated using in vitro degradation assays. BxPC-3 cells stably transfected to overexpress hK7
were used to examine the effect of hK7 on cell-surface resident Dsg2.
Results:  The levels of immunoreactive Dsg1 and Dsg2 were reduced in pancreatic
adenocarcinomas compared with both normal pancreatic and chronic pancreatitis tissues. Among
the desmosomal proteins examined, Dsg2 exhibited robust expression on the surface of BxPC-3
cells. When hK7 was overexpressed in this cell line, there was a significant increase in the amount
of soluble Dsg2 released into the culture medium compared with vector-transfected control cells.
Conclusion: A reduction in the amount of the cell adhesion components Dsg1 and Dsg2 in
pancreatic tumors suggests that loss of these desmosomal proteins may play a role in pancreatic
cancer invasion. Using in vitro degradation assays, both Dsg1 and Dsg2 could be readily proteolyzed
by hK7, which is overexpressed in pancreatic adenocarcinomas. The enforced expression of hK7
in BxPC-3 cells that express significant amounts of Dsg2 resulted in a marked increase in the
shedding of soluble Dsg2, which is consistent with the notion that aberrant expression of hK7 in
pancreatic tumors may result in diminished cell-cell adhesion and facilitate tumor cell invasion.
Background
Pancreatic cancer is one of the deadliest of all human can-
cers, resulting in more than 30,000 deaths per year in the
United States alone, and continues to be a major health
problem in terms of detection as well as treatment. Pan-
creatic cancer is highly invasive and is characterized by
early metastasis. Tumor invasion and metastasis is a
multi-step process involving several key cellular events
[1]. Among the many events leading to tumor dissemina-
tion and metastasis, loss of intracellular adhesion is one
of the earliest events [2].
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Among the classes of adhesion molecules, desmosomes
have been widely recognized and studied for their various
roles in cell adhesion, tissue morphogenesis, and cell sig-
naling [3]. Desmosomes, apart from being adhesive intra-
cellular junctions, also act as a membrane anchor for
intermediate filaments [4]. The core of the desmosomal
adhesive complex primarily consists of desmogleins (Dsg)
and desmocollins (Dsc), glycoproteins belonging to the
cadherin superfamily of proteins. At least four different
isoforms of desmogleins (Dsg1–4) and three different iso-
forms of desmocollins (Dsc1–3) have been reported thus
far. As seen with many other important adhesion mole-
cules, alterations in the expression of various members of
desmosomal family of proteins have been observed in dif-
ferent types of cancer [5]. There is, however, a lack of com-
plete understanding regarding the expression of
desmosomal proteins in many different types of cancer
and the mechanism by which cancer cells may regulate
and overcome the adhesion mediated by desmosomal
proteins.
One of the most well characterized mechanisms by which
tumor cells can overcome adhesion mediated by intercel-
lular adhesive molecules is by up-regulating the expres-
sion of various families of proteases that are capable of
proteolyzing one or more of these cellular adhesions [6-
9]. Among the various families of proteases, the kal-
likreins are known to play an important role in many dif-
ferent disease states, including cancer [10-12]. In a
previous study, we have reported that kallikrein 7 (KLK7/
hK7) is overexpressed in pancreatic adenocarcinomas and
enhances pancreatic cancer cell invasion by shedding E-
cadherin [13]. Human kallikrein 7 (hK7), originally
named stratum corneum chymotryptic enzyme, was ini-
tially characterized from extracts of human skin and
shown to play an important role in normal skin desqua-
mation by degrading desmogleins and corneodesmo-
somes [14,15] along with other kallikreins [16]. However,
the effects of hK7 expression on desmosomal proteins in
any type of cancer, including pancreatic cancer where
overexpression of KLK7/hK7 has been clearly established,
have not been studied. Herein, we show for the first time
that the overall expression levels of desmogleins 1 and 2
are lower in human pancreatic adenocarcinomas com-
pared to chronic pancreatitis and non-malignant pancre-
atic tissues and that both of these desmosomal proteins
are substrates for hK7. Additionally, expression of KLK7 in
the human pancreatic adenocarcinoma cell line BxPC-3
significantly increased the amount of soluble desmoglein
2 shed from the cell surface, which correlates with the in
vitro degradation data. These results extend the potential
roles for the aberrant expression of hK7 observed in pan-
creatic cancer and points toward a critical role for this pro-
tease in aiding cancer invasion via its action on important
cellular adhesive molecules like desmogleins.
Methods
Immunohistochemistry
For each antigen examined, formalin-fixed, paraffin-
embedded tissue blocks from six non-malignant pancreas,
six chronic pancreatitis, and six pancreatic adenocarci-
noma tissues were prepared for immunohistochemical
analysis. Representative hematoxylin and eosin-stained
sections from each tissue were evaluated by microscopic
analysis. Sections (4 μm) were deparaffinized and rehy-
drated in xylene followed by graded ethanol. Antigen
retrieval was performed in a 95°C water bath using 10
mM citrate, pH 6.0, for 30 minutes. Endogenous peroxi-
dase activity was quenched by hydrogen peroxide treat-
ment followed by serum-free protein block
(DakoCytomation, Carpinteria, CA). Sections were incu-
bated with desmoglein 1, 2, or 3 antibodies (R&D Sys-
tems, Minneapolis, MN), diluted 1:75 in antibody diluent
(DakoCytomation), overnight at 4°C. Immunoreactive
staining was detected using a DAKO LSAB+ peroxidase
system followed by hematoxylin counterstain. Using
direct ELISA and western blot analyses to examine the spe-
cificity of the desmoglein antibodies, the supplier reports
that the Dsg1 antibody shows approximately 5% cross-
reactivity with rhDesmoglein-2 and the Dsg2 antibody
shows less than 1% cross-reactivity with rhDesmoglein-1.
The acquisition and use of archived, paraffin-embedded
human tissue samples in this study were reviewed and
approved by the UAMS Human Research Advisory Com-
mittee.
Quantitation of immunohistochemical staining
To numerically analyze the immunohistochemical stain-
ing, virtual slides were created from the stained samples
after scanning each specimen using an Aperio ScanScope
scanning system (Aperio Technologies, Vista, CA). The
ScanScope generated true color digital images of each
stained sample, which were viewed using Aperio Image-
scope v.6.25 software. The algorithm for determining the
intensity of membrane-specific staining provided by the
manufacturer was optimized and used to calculate the
staining intensity and percent target labeled for each sam-
ple by digitally analyzing the color intensity. A color
markup image for each slide was obtained based on mem-
brane staining intensity. The output was viewed as deter-
minations of staining intensity ranging from 0+ to 3+ to
correlate with conventional manual scoring methods and
the percentage of cells stained for either Dsg1 or Dsg2 was
averaged for non-malignant, pancreatitis, pancreatic can-
cer samples and represented as a stacked column graph.
In vitro degradation assays
Recombinant, pro-hK7 (100 μg/mL) (R&D Systems) was
proteolytically activated using 10 μg/ml thermolysin
(R&D Systems) and its proteolytic activity was verified
using a fluorogenic substrate, ES002 (R&D Systems),BMC Cancer 2008, 8:373 http://www.biomedcentral.com/1471-2407/8/373
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according to manufacturer's instructions. Thermolysin-
activate hK7 (25 ng) was then added to 100 ng of either
recombinant Dsg1 or Dsg2 (R&D Systems). The mixtures
were split into two fractions and thermolysin activity was
inhibited in both the fractions with 0.4 mM (final concen-
tration) phosphoramidon (Sigma-Aldrich, St. Louis,
MO). As a control, chymostatin was added (0.28 mM final
concentration) to one fraction to inhibit hK7 activity. All
the samples were incubated at 37°C and at 30 minute
intervals an aliquot was removed from each mixture,
added to SDS-PAGE sample buffer, heated at 95°C for 5
minutes, and stored at 4°C for further analysis. At the end
of the incubation period, all the samples were separated
using 4–12% gradient Bis-Tris NuPAGE gels (Invitrogen,
Carlsbad, CA) and transferred to PVDF membranes. The
membranes were blocked with a 5% non-fat milk solu-
tion in Tris-buffered saline, pH 7.4, containing 0.1%
Tween-20 (TTBS) then incubated overnight at 4°C with
either Dsg1 or Dsg2 antibody (R&D Systems) diluted
1:1250 with TTBS. After washing with TTBS, the blots were
incubated for 1 hour at room temperature with HRP-con-
jugated polyclonal anti-goat immunoglobulins (DakoCy-
tomation) diluted 1:2000 in TTBS. The blots were washed
with TTBS and visualized by chemiluminescence using
ECL plus reagent (GE Healthcare, Piscataway, NJ) and a
ChemiDoc XRS image documentation system and Quan-
tity One analysis software (Bio-Rad, Hercules, CA).
Immunoblotting for Dsg1 and Dsg2 in pancreatic cancer 
cell lines
Human pancreatic adenocarcinoma cell lines Panc-1 and
BxPC-3 (American Type Culture Collection, Manassas,
VA) were grown in 10-cm plates at 37°C in a 5% CO2
incubator in Dulbecco's modified Eagle's medium
(DMEM) (Invitrogen) containing 10% fetal bovine serum
(Atlanta Biologicals, Norcross, GA). Confluent monolay-
ers were harvested by scraping, washed twice with phos-
phate-buffered saline (PBS), and lysed with RIPA buffer (1
mM EDTA, 1% NP-40, 0.5% deoxycholate, 0.1% SDS in
PBS) containing Complete protease inhibitor cocktail
(Roche, Indianapolis, IN). The cell lysates were sonicated
on ice and centrifuged at 13,000 rpm to remove any cell
debris and the protein concentration of each lysate was
determined using a bicinchoninic acid assay (BCA)
(Sigma-Aldrich). Two samples of each lysate (50 μg of
total protein) were resolved by SDS-PAGE and transferred
to PVDF membrane. The membrane was cut and probed
for Dsg1 or Dsg2 (upper portion) and GAPDH (lower
portion) by western blot.
Immunocytochemistry
Panc-1 and BxPC-3 cells (3 × 104) were seeded in Lab-Tek
II four-chamber glass slides (Nalge Nunc, Naperville, IL).
Confluent monolayers were washed twice with PBS then
fixed with 4% paraformaldehyde in PBS at room temper-
ature for 20 minutes. The fixed cells were washed with
PBS, permeabilized with -20°C chilled methanol, washed
with PBS, and incubated with serum-free protein block
(DAKO). The cells were then incubated overnight at 4°C
with a polyclonal Dsg2 antibody (diluted 1:75), washed
with PBS containing 0.1% Triton X-100 (TPBS), and incu-
bated with a fluorescein isothiocyanate (FITC)-conju-
gated rabbit anti-goat antibody (DakoCytomation) for 2
hours at room temperature. Cells were washed with TPBS,
mounted with Vectashield mounting medium (Vector
Laboratories, Burlingame, CA), and visualized using an
Olympus BX41 fluorescent microscope (Olympus USA,
Melville, NY). Images were captured with a SPOT-RT dig-
ital camera and software (Diagnostic Instruments, Sterling
Heights, MI).
Detection of soluble desmoglein 2
One million vector-transfected or KLK7-expressing BxPC-
3 cells [17] were seeded in 10-cm dishes. Growth medium
from confluent monolayers was removed, cells were
washed twice with serum-free medium (SFM), and then
incubated in SFM containing 1.5 μg/ml puromycin for 24
hours. The conditioned medium was removed and centri-
fuged at 1500 rpm for 5 minutes at 4°C to remove
detached cells and debris and then concentrated using
Amicon Ultra-4 centrifugal filter units, 10-kDa nominal
molecular weight limit (Millipore, Billerica, MA), accord-
ing to manufacturer's instructions. The cell monolayers
were harvested by trypsinization and single-cell suspen-
sions were prepared and enumerated using a Z1 Coulter
counter (Beckman Coulter, Fullerton, CA). The total
number of cells per volume of final concentrate for each
sample was calculated and the volume of concentrate cor-
responding to 106 cells for each sample was mixed with
SDS sample buffer and heated at 95°C for 5 minutes. The
samples were then separated using a NuPage 4–12% gra-
dient polyacrylamide gel (Invitrogen) and transferred to a
PVDF membrane. The immunoblot was blocked with a
5% non-fat milk solution in TTBS then incubated over-
night with anti-Dsg2 polyclonal antibody (diluted
1:1250) (R&D Systems). After washing with TTBS, the blot
was incubated with horseradish peroxidase-(HRP) conju-
gated anti-goat immunoglobulins (diluted 1:2000)
(DakoCytomation) and soluble Dsg2 (sDsg2) was visual-
ized by chemiluminescence using ECL plus reagent and a
ChemiDoc XRS image documentation system. The
amount of sDsg2 released into the conditioned medium
of each sample was quantified using Quantity One image
analysis software. The mean intensity of three independ-
ent experiments was determined and analyzed for statisti-
cal significance using an unpaired, 2-tailed t-test
(GraphPad Software, San Diego, CA).BMC Cancer 2008, 8:373 http://www.biomedcentral.com/1471-2407/8/373
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Results
Intensity of membrane staining for desmosomal proteins 
Dsg1 and Dsg2 is lower in human pancreatic cancer 
compared to normal pancreas and chronic pancreatitis
Six independent sections of normal human pancreas,
chronic pancreatitis, or pancreatic adenocarcinoma tissue
were stained for desmogleins 1, 2, and 3. Desmogleins 1
and 2 were clearly present in all of the normal pancreatic
tissue samples examined and showed intense staining at
the cell-cell borders (Fig. 1A and 2A, respectively). In con-
trast, Dsg3 was not detected in any of the pancreatic tis-
sues (data not shown). The chronic pancreatitis samples
showed staining intensity and distribution similar to the
normal pancreatic samples for Dsg1 (Fig. 1B) and Dsg2
(Fig. 2B). All the pancreatic cancer samples displayed an
intense desmoplastic response, the synthesis and deposi-
tion of collagenous material by stromal myofibroblasts
surrounding the adenocarcinoma, and the membrane
staining for both Dsg1 (Fig. 1C) and Dsg2 (Fig. 2C) was
distinctly weaker in most of the cancer samples analyzed.
The correspondence between increased hK7 expression in
pancreatic tumors and loss of Dsg2 is highlighted in the
immunohistochemistry studies we have performed. For
example, the tumor section stained for Dsg2 (Figure 2C,
this study), showing a loss of Dsg2 immunoreactivity, is
from the same tissue used to demonstrate increased hK7
expression in pancreatic tumors (Figure 2A, ref. [13]).
To further quantify the intensity of membrane staining for
Dsg1 and Dsg2 in the different tissue samples, the stained
slides were scanned with an Aperio ScanScope and areas
of cellularity in the digital images were selected by a
pathologist (L.H.) and processed to calculate the staining
intensity and percent label for each sample. The average
percentage of cells stained for Dsg1 within each intensity
category (e.g., 1+, 2+) was nearly equal between the nor-
mal pancreatic tissues and chronic pancreatitis samples
(Fig. 1D). The pancreatic cancer samples, however,
showed an almost complete loss of cells displaying
intense (3+) Dsg1 staining and a marked decrease in cells
with 2+ intensity with a concomitant increase in cells with
weak (1+) or absent (0+) Dsg1 staining.
An examination of Dsg2 immunoreactivity revealed that
the most intense staining (3+) was observed in the normal
pancreatic tissues (28.4%), although the chronic pancrea-
titis samples (11.2%) still showed a higher average per-
centage of cells with 3+ intensity compared to the
pancreatic adenocarcinoma samples (4.3%) (Fig. 2D).
The average number of cells with 2+ intensity of staining
was nearly equal in the normal and chronic pancreatitis
samples and somewhat higher in pancreatic cancer sam-
ples, while the number of cells with (1+) intensity was
higher in chronic pancreatitis (47.8%) and pancreatic
cancer (47.7%) samples compared with the normal pan-
Desmoglein 1 is present in lower levels in pancreatic cancer  compared to normal and chronic pancreatitis tissue Figure 1
Desmoglein 1 is present in lower levels in pancreatic 
cancer compared to normal and chronic pancreatitis 
tissue. Representative pancreatic tissue sections stained for 
Dsg1 showed high membrane staining in (A) normal pan-
creas, (B) chronic pancreatitis (CP), and (C) weaker staining 
in pancreatic adenocarcinoma (PaC) samples. Original magni-
fication x400. (D) Staining intensity of the cell membranes 
was quantitated (see Methods), categorized into intensity 
ranges from 0+ to 3+, and the average percentage of cells in 
each group was determined and represented in a stacked 
graph for each tissue type (n = 6).BMC Cancer 2008, 8:373 http://www.biomedcentral.com/1471-2407/8/373
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creatic tissues (30%). Although the percentage of cells
lacking demonstrable Dsg2 staining (0+) increased with
the severity of disease (i.e., pancreatic cancer > chronic
pancreatitis > normal pancreas), the numbers were mod-
est in all three tissue types. (Fig. 2D). Thus, overall the
average intensity of membranous desmoglein staining
was decreased in adenocarcinomas compared to normal
pancreas and pancreatitis samples.
hK7 cleaves both recombinant Dsg1 and Dsg2 in vitro
To determine whether hK7 could participate in decreasing
the levels of Dsg1 and Dsg2 through proteolytic cleavage,
in vitro degradation assays were performed using recom-
binant hK7 and desmosomal proteins. Upon incubation
with thermolysin-activated hK7, recombinant Dsg1 was
rapidly degraded with little detectable protein remaining
after 60 minutes (Fig. 3A, left). Recombinant Dsg2 was
also cleaved by hK7 in a time-dependent manner, how-
ever, in contrast to the complete proteolysis of Dsg1, the
cleavage of Dsg2 resulted in distinct proteolytic fragments
(Fig. 3B, left). All of the degradation assays were per-
formed in the presence of phosphoramidon, which inhib-
its the thermolysin used to activate hK7. To verify that the
degradation of the desmogleins was due to hK7 activity
and not due to any residual activity of thermolysin, a par-
allel set of assays was performed that included chymosta-
tin, an oligopeptide that inhibits serine proteases with
chymotrypsin-like substrate specificity (Figs. 3A and 3B,
right). Proteolysis of both the desmosomal proteins by
hK7 was effectively inhibited in the presence of chymosta-
tin.
Levels of desmogleins in human pancreatic cancer cells
To identify pancreatic cancer cell lines that could be used
to examine hK7-dependent cleavage of desmosomal pro-
teins in a cell-based system, cell lysates were prepared
from Panc-1 and BxPC-3 cell lines and assessed for the lev-
els of Dsg1 and Dsg2 by western blot analysis. Dsg1 was
not detected in either of the cell lines (Fig. 4A, lanes 1 and
2), whereas Dsg2 was readily detected in BxPC-3 but not
Panc-1 cell lysates (Fig. 4A, lanes 3 and 4, respectively).
Due to the significant expression of Dsg2 in BxPC-3 cell
lysates, immunocytochemical staining was performed on
intact cells to determine its cellular localization and distri-
bution. The staining revealed a robust cell-cell border dis-
tribution similar to the pattern seen in epithelial tissues
(Fig. 4B).
Effect of hK7 expression on Dsg2 in BxPC-3 pancreatic 
cancer cells
Since BxPC-3 cells exhibit significant amounts of Dsg2,
but do not express hK7 (data not shown), these cells were
utilized to investigate the effects of enforced hK7 expres-
sion on Dsg2 in a cell-based system. BxPC-3 cells were
transfected with a KLK7-expression construct or empty
Desmoglein 2 staining is lower in pancreatic cancer cell  membranes compared to normal and chronic pancreatitis tis- sue Figure 2
Desmoglein 2 staining is lower in pancreatic cancer 
cell membranes compared to normal and chronic 
pancreatitis tissue. Representative pancreatic tissue sec-
tions stained for Dsg2 showed high levels of membrane stain-
ing in (A) normal pancreas and (B) chronic pancreatitis (CP) 
samples. Membrane staining was much weaker in (C) pancre-
atic adenocarcinoma (PaC) samples. Original magnification 
x400. (D) Staining intensity of the cell membranes was quan-
titated (see Methods), categorized into intensity ranges from 
0+ to 3+, and the average percentage of cells in each group 
was determined and represented in a stacked graph for each 
tissue type (n = 6).BMC Cancer 2008, 8:373 http://www.biomedcentral.com/1471-2407/8/373
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vector and stable transfectants were generated [17]. To
obviate clonal effects, two independent KLK7-expressing
clones, BxPC-3/hK7 clone#3 and BxPC-3/hK7 clone#7,
were analyzed and compared to a vector-transfected con-
trol clone, BxPC-3/Vec. To examine the cleavage of Dsg2
from the cell surface in the presence of hK7, concentrated
conditioned medium from hK7-expressing and vector-
transfected control cells was prepared and the level of sol-
uble Dsg2 was determined by western blot. Both of the
hK7-expressing clones examined displayed higher levels
of an 80-kDa soluble Dsg2 product compared to the vec-
tor-transfected clone (Fig. 5); thus supporting the notion
that aberrant expression of hK7 may lead to the cleavage
of Dsg2 from the cell surface.
Discussion
Cell-cell adhesion and cell-extracellular matrix adhesion
play a critical role as limiting factors during the early steps
of invasion [1,18,19]. Various classes of cell adhesion
Desmoglein 1 and 2 are substrates for hK7 in vitro Figure 3
Desmoglein 1 and 2 are substrates for hK7 in vitro. 
Thermolysin-activated hK7 was incubated with recombinant 
Dsg1 (A) or Dsg2 (B) for the indicated times in the absence 
(lanes 1–4) or presence (lanes 5–8) of the hK7 inhibitor chy-
mostatin. Reaction products were separated by SDS-PAGE 
and visualized by western blot using either anti-Dsg1 or anti-
Dsg2 antibodies. Sizes of protein markers are indicated on 
the left.
Expression of desmogleins in human pancreatic adenocarci- noma cell lines Figure 4
Expression of desmogleins in human pancreatic ade-
nocarcinoma cell lines. (A) Equal amounts of total protein 
from whole cell lysates of human pancreatic cancer cell lines 
BxPC-3 (lanes 1 and 3) and Panc-1 (lanes 2 and 4) were sepa-
rated by SDS-PAGE and visualized by western blot using anti-
Dsg1 and anti-Dsg2 antibodies, as indicated. GAPDH levels 
were monitored as a loading control (arrowhead). Sizes of 
protein markers are indicated on the left. Appreciable levels 
of Dsg2 were detected in BxPC-3 cells, but not in Panc-1 
cells. Dsg1 was not detected in either of the cell lines. (B) 
Immunocytochemistry of Dsg2 in BxPC-3 cells using a FITC-
conjugated secondary antibody showed specific cell mem-
brane localization. Original magnification x400.BMC Cancer 2008, 8:373 http://www.biomedcentral.com/1471-2407/8/373
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molecules, including desmosomes, are affected in differ-
ent types of cancer and tumor cells can regulate the expres-
sion and function of these adhesive molecules via various
mechanisms [20,21]. Components that comprise these
intercellular junctions play a critical role in determining
the function and strength of these adhesive complexes
[22]. Desmogleins and desmocollins, along with pla-
koglobin, desmoplakin, and plakophilin, represent the
essential and minimum number of components that can
form an intact functional desmosome [23,24]. Desmo-
gleins, which form an integral part of the desmosomal
adhesive core, are affected in many types of cancer. Vari-
ous desmoglein proteins have been shown to be downreg-
ulated in urothelial carcinoma [25], oral squamous cell
carcinoma [26,27], esophageal squamous cell carcinoma
[28], and squamous intraepithelial lesions of the cervix
[29]. Desmosomal constituents, like Dsg2, have been
demonstrated to be expressed abnormally in gastric can-
cer [30] and its decreased expression has been associated
with poorer prognosis for diffuse-type gastric cancer [31].
However, a clear understanding of the expression levels of
desmogleins and the possible mechanisms leading to
their decreased expression in other types of cancer, like
pancreatic cancer, is still lacking.
Kallikrein 7, a chymotryptic-like serine protease that is
prevalent in the stratum corneum, has been shown to
directly cleave corneodesmosomes and desmosomes in
vitro [32]; thus implicating its participation in desquama-
tion in normal human skin [33]. Studies have also shown
that hK7 is overexpressed in squamous cervical cancerous
cells [34], ovarian tumor cells [35,36], cervical adenocar-
cinomas [37], and in lung cancer [38]. Moreover, recently
we have further demonstrated that KLK7/hK7 is overex-
pressed in pancreatic adenocarcinomas [13]. However,
the ability of hK7 expressed in any of these cancers to act
upon desmosomal proteins, like desmogleins, which are
substrates for hK7 in normal physiology, has never been
explored.
Based on the aberrant expression of hK7 in pancreatic can-
cer, in this study we sought to determine whether the des-
mogleins may be substrates of hK7 in pancreatic cancer.
The expression and distribution of individual desmo-
somal cadherins is tissue specific [39]. For example, Dsg2
is ubiquitously expressed in all tissues containing desmo-
somes [40], whereas Dsg1 and Dsg3 are mainly restricted
to stratified squamous epithelia [41]. In the epidermis,
Dsg1 is expressed throughout the upper differentiating
cell layers, while Dsg3 is restricted to basal keratinocytes
[41]. Thus, as a positive control we stained sections of nor-
mal human skin with the Dsg1 antibody used to detect its
expression in pancreatic tissues (Additional file 1). Con-
sistent with previous findings [42], Dsg1 was detected
throughout the epidermis from superficial to basal layers.
In recent studies in mice, the presence of DSG1 and DSG3
mRNAs have been reported in many epithelial organs
[41]. As a first step, we surveyed human pancreatic tissue
samples representing non-malignant, chronic pancreati-
tis, and pancreatic cancer specimens for the expression of
desmoglein proteins by immunohistochemistry. Upon
analysis, both desmogleins 1 and 2 showed intense mem-
brane staining in normal pancreas and chronic pancreati-
Levels of soluble Dsg2 in conditioned medium of KLK7- expressing BxPC-3 cells are higher than in vector-transfected  control cells Figure 5
Levels of soluble Dsg2 in conditioned medium of 
KLK7-expressing BxPC-3 cells are higher than in vec-
tor-transfected control cells. (A) Levels of soluble Dsg2 
(sDsg2) in concentrated conditioned medium from hK7-
expressing clones BxPC-3/hK7 clone#3 (lane 1) and clone#7 
(lane 2) and vector-transfected clone BxPC-3/Vec (lane 3) 
were determined by western blot. Sizes of protein markers 
are indicated on the left. (B) The relative amount of the 80-
kDa sDsg2 immunoreactive product was determined for 
KLK7-transfected (solid bars) and vector-transfected (open 
bar) BxPC-3 cells by densitometric analysis using Quantity 
One software and the average relative intensity is depicted. 
Vertical bars represent SEM (n = 3).BMC Cancer 2008, 8:373 http://www.biomedcentral.com/1471-2407/8/373
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tis samples. The intensity of staining for both these
desmosomal proteins, however, was qualitatively much
weaker in pancreatic cancer tissues. To quantitate the
intensity of the membrane staining in a more objective
manner, the stained sections were scanned and the digital
images processed to produce a numerical representation
of the staining intensity and stratification into groups typ-
ically reported in a manual analysis by a pathologist (e.g.,
3+ staining). This analysis revealed that the average per-
centage of cells within each intensity group was similar for
Dsg1 between the non-malignant and chronic pancreatitis
samples, but that the percentage of more intensely stained
cells for Dsg1 decreased markedly in the pancreatic cancer
samples. In contrast, with Dsg2 the average number of
cells with intense staining (3+) was markedly higher in
non-malignant pancreas samples compared to either of
the other two diseased conditions. With both Dsg1 and
Dsg2, there was a pronounced shift toward the lower
intensity categories in the pancreatic cancer samples.
Thus, there appeared to be a clear inverse correlation
between the expression of hK7 and the membrane inten-
sity of desmosomal proteins in pancreatic samples from
diseased and non-diseased conditions. No appreciable
Dsg3 immunoreactivity could be detected in any of the
pancreatic tissue samples. Since the ability of the antibod-
ies used to detect Dsg3 by immunohistochemistry was
verified using sections of normal human skin as a positive
control (data not shown), these findings indicate that
Dsg3 is not expressed at detectable levels in human pan-
creas.
To provide more direct evidence for a relationship
between hK7 expression and the decreased intensity of
desmogleins observed by immunohistochemistry, in vitro
substrate degradation assays were performed. In support
of an association between hK7 and the desmogleins, hK7
was able to proteolyze both Dsg1 and Dsg2. Proteolysis of
Dsg1 resulted in a rapid degradation of recombinant Dsg1
into fragments undetectable by western blot. Interest-
ingly, incubation of Dsg2 with hK7 resulted in cleavage of
Dsg2 into distinct fragments rather than indiscriminant
degradation. As further evidence of the specificity of hK7,
we have tested other potential substrates under similar
conditions. For example, when laminin was incubated
with activated hK7, no significant cleavage was observed
even after 24 hours (Additional file 2); thus, not all pro-
teins are subject to hK7-directed proteolysis.
To identify a pancreatic cancer cell-based model to further
examine the proteolysis of desmogleins by hK7, cell
lysates from two pancreatic cancer cell lines, BxPC-3 and
Panc-1, were screened for Dsg1 and Dsg2 by western blot
analysis. This revealed that only Dsg2 was expressed in
appreciable levels in BxPC-3 cells. Since BxPC-3 cells do
not express hK7, we used these cells to mimic the aberrant
expression of KLK7  observed in pancreatic tumors by
expressing high levels of hK7 through stable transfection.
In this manner, the effects on Dsg2 in cells with and with-
out  KLK7  expression could be compared, which could
yield insights into changes in desmosomal proteins upon
hK7 expression. In BxPC-3 cells expressing hK7, a marked
increase in the shedding of an 80-kDa sDsg2 fragment was
observed compared to a vector-transfected control. These
findings suggest that decreased levels of desmosomal pro-
teins seen in pancreatic cancer may result from the action
of hK7 overexpressed in these tumors.
A comparison of KLK7-transfected and vector-transfected
pancreatic cancer cells reveals that hK7 expression alters
cell morphology (Additional file 3), with cells expressing
hK7 exhibiting a more flattened, less refractive appearance
and reduced cell-cell contacts. Using in vitro assays, we
have demonstrated that hK7 can cleave both E-cadherin
[13] and desmogleins (this report) independently. In cell-
based assays where both E-cadherin and desmogleins
(Dsg2) are present, we can not dissect whether the action
of hK7 upon a particular substrate is a primary or second-
ary effect, or whether both substrates are acted upon con-
currently. Based upon our in vitro results, we favor the
notion that hK7 cleaves each substrate from the cell sur-
face independently, with their combined loss contribut-
ing to the morphological changes observed. Other hK7
substrates that have yet to be elucidated, however, may
also participate in this process.
Conclusion
In this report we have shown that the levels of cell-surface
resident Dsg1 and Dsg2 are reduced in pancreatic adeno-
carcinomas compared with normal and chronic pancrea-
titis tissues. We have also demonstrated that these
desmosomal proteins are substrates of the chymotryptic-
like protease hK7, which is overexpressed in pancreatic
cancer. Using a cell-based system, we have found that
expression of hK7 results in a marked increase in the shed-
ding of an 80-kDa soluble fragment of Dsg2 into the con-
ditioned medium of BxPC-3 cells. These results, therefore,
provide evidence that hK7 may play a critical role in the
invasion of cancer cells in which it is aberrantly expressed
by degrading important cell adhesive molecules like des-
mogleins and E-cadherin [13].
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